Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial-Reference-Cited by-同舟云学术

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial

Published:2014-01-30 Issue:1 Volume:9 Page:e86663
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kamm Christian P.,El-Koussy Marwan,Humpert Sebastian,Findling Oliver,Burren Yuliya,Schwegler Guido,Donati Filippo,Müller Martin,Müller Felix,Slotboom Johannes,Kappos Ludwig,Naegelin Yvonne,Mattle Heinrich P.,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Effect of Pravastatin on Outcomes after Cardiac Transplantation;JA Kobashigawa;N Engl J Med,1995

2. The immunopathology of multiple sclerosis. An overview;H Lassmann;Brain Pathol,2007

3. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin;R Stanislaus;Neurosci Lett,1999

4. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis;R Stanislaus;J Neurosci Res,2001

5. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease;S Youssef;Nature,2002

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

2. A review on the efficacy and safety of lipid-lowering drugs in neurodegenerative disease;Reviews in the Neurosciences;2023-04-10

3. Statins in Liver Cirrhosis;Pharmacotherapy for Liver Cirrhosis and Its Complications;2022

4. The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2021-11

5. Statins for treatment of chronic liver disease;Current Opinion in Gastroenterology;2021-03-01